SOURCE: National Disability Institute

National Disability Institute

July 08, 2013 10:12 ET

Third Annual Financial Wellness Webinar Series for People Living With Multiple Sclerosis to Launch July 17, 2013

National Disability Institute's Free Webinar Series Sponsored by Acorda Therapeutics to Provide Information on How People With MS Can Chart a Course to Financial Wellness

WASHINGTON, DC--(Marketwired - July 08, 2013) -  On July 17, 2013, National Disability Institute will launch a new series of six free national webinars designed to help people living with multiple sclerosis (MS) plan for their financial futures. National Disability Institute's Financial Wellness Webinar Series sponsored by Acorda Therapeutics will feature experts in financial capability, favorable tax provisions, disability benefits and other areas outlining important options specifically for people with MS related to taxes, public benefits and healthcare subsidies, employment and other areas of personal finance. The new series marks the third consecutive year the Financial Wellness Webinar Series will be offered, with topics selected based on last year's participant feedback. More than 1,300 people registered for the webinars in 2012.

The webinar series launch coincides with the 23rd anniversary of the Americans with Disabilities Act (ADA), the federal civil rights law that protects individuals with disabilities from discrimination and ensures equal access and opportunity. In 2011, National Disability Institute conducted an online survey of 3,000 people living with MS, with 67 percent of respondents reporting their financial positions declined after their MS diagnosis. In addition, 74 percent reported that they did not use financial planning programs or strategies to manage or stabilize their finances. The Financial Wellness Webinar Series will connect people living with MS to vital information and tools designed to advance their overall financial capability.

The first Financial Wellness Webinar will be held Wednesday, July 17th at 3:00 p.m. ET and will last 90 minutes. Subsequent webinars will be held on the third Wednesday of each month through December 2013. Each webinar consists of a one-hour expert presentation followed by a half-hour set aside for participant questions. Guest speakers who live with MS will offer a peer perspective during each webinar as well. There is no cost to participate in the webinars, but registration is required. Visit for more information and to register for any of the six webinars in the series:

  • July 17: Financial Education - Charting a Course to Financial Wellness
  • August 21: Your Home - Owning, Refinancing & Modifying
  • September 18: Social Security Disability Insurance - The Impact of Work on Benefits
  • October 16: Prolonging Work Supports to Keep You on the Job
  • November 20: The NEW Healthcare Changes and You
  • December 18: Favorable Tax Deductions for Individuals with Disabilities

* Webinar topics are subject to change.

"This unique webinar series is a free, no-risk opportunity for people living with MS to take positive steps toward improving their financial futures -- for themselves and their families. Each program includes easy-to-understand information to help people with MS manage their money, understand their rights and responsibilities, and develop a smart savings and investment plan for the future," said Michael Morris, executive director of National Disability Institute. "Expanding knowledge is a vital first step toward promoting financial capability and stability for people living with MS and for all people with disabilities."

"Our mission at Acorda is to improve the lives of people affected by neurological diseases, and our support for the Financial Wellness Webinar series at National Disability Institute is an important reflection of that mission," said Tierney Saccavino, Senior Vice President of Corporate Communications at Acorda Therapeutics. "It is often very difficult for people living with MS to find information about financial matters that addresses their specific and unique challenges. This webinar series addresses a significant need and we at Acorda are grateful for the opportunity to once again sponsor this groundbreaking program for the MS community."

On Friday, July 12that 3:00 p.m. ET, National Disability Institute will host a live chat on Twitter to preview the Financial Wellness Webinar series topics and create an open forum for the discussion of financial issues faced by people living with MS. Join the chat by following @RealEconImpact and using the hashtag #FWFriday. National Disability Institute will select participants from the Twitter chat to author a guest post that will be published on the organization's blog at

About National Disability Institute

National Disability Institute is a national nonprofit organization dedicated to building a better economic future for people with disabilities. The first national organization committed exclusively to championing economic empowerment, financial education, asset development and financial stability for all persons with disabilities, National Disability Institute effects change through public education, policy development, training, technical assistance and innovative initiatives. Since 2005, National Disability Institute and its Real Economic Impact (REI) Network of more than 900 partners in more than 100 cities nationwide have helped 1.5 million people with disabilities receive more than $1.4 billion in tax refunds. To learn more, visit

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.

Acorda markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.

The Company also markets ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda also receives sales royalties on tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES, distributed by Actavis, Inc. under its agreement with Acorda.

Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is developing Diazepam Nasal Spray for treatment of certain epileptic seizures. It is also studying AMPYRA to improve a range of functional impairments caused by MS, as well as its potential for use in other neurological conditions, including cerebral palsy and post-stroke deficits. In addition, Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury, GGF2 for treatment of heart failure and rHIgM22, a remyelinating monoclonal antibody, for the treatment of MS. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and peripheral nerve damage. Chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury, is in preclinical development.

The following files are available for download:

Contact Information